Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Dogwood Therapeutics (NASDAQ: DWTX) has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event will take place on May 14, 2025, at The Plaza Hotel in New York City. CEO and Chairman Greg Duncan will be available for one-on-one meetings with interested parties from 9:00 A.M. to 3:00 P.M. (ET). Those interested in scheduling meetings can contact John Perez at jperez@dboralcapital.com for registration.
Dogwood Therapeutics (NASDAQ: DWTX) ha annunciato la sua partecipazione al prossimo D. Boral Capital Inaugural Global Conference. L'evento si terrà il 14 maggio 2025 presso il The Plaza Hotel di New York City. Il CEO e Presidente Greg Duncan sarà disponibile per incontri individuali con le parti interessate dalle 9:00 alle 15:00 (ET). Chi desidera fissare un appuntamento può contattare John Perez all'indirizzo jperez@dboralcapital.com per la registrazione.
Dogwood Therapeutics (NASDAQ: DWTX) ha anunciado su participación en la próxima D. Boral Capital Inaugural Global Conference. El evento se llevará a cabo el 14 de mayo de 2025 en The Plaza Hotel en la ciudad de Nueva York. El CEO y presidente Greg Duncan estará disponible para reuniones individuales con las partes interesadas de 9:00 a.m. a 3:00 p.m. (ET). Quienes deseen programar reuniones pueden contactar a John Perez en jperez@dboralcapital.com para registrarse.
Dogwood Therapeutics (NASDAQ: DWTX)가 다가오는 D. Boral Capital Inaugural Global Conference에 참여한다고 발표했습니다. 행사는 2025년 5월 14일 뉴욕시 플라자 호텔에서 개최됩니다. CEO 겸 회장 Greg Duncan은 오전 9시부터 오후 3시(동부시간)까지 관심 있는 분들과 1:1 미팅을 진행할 예정입니다. 미팅 예약을 원하시는 분은 jperez@dboralcapital.com의 John Perez에게 연락해 등록할 수 있습니다.
Dogwood Therapeutics (NASDAQ : DWTX) a annoncé sa participation à la prochaine D. Boral Capital Inaugural Global Conference. L'événement aura lieu le 14 mai 2025 au Plaza Hotel de New York. Le PDG et président Greg Duncan sera disponible pour des réunions individuelles avec les parties intéressées de 9h00 à 15h00 (heure de l'Est). Les personnes souhaitant planifier des rendez-vous peuvent contacter John Perez à l'adresse jperez@dboralcapital.com pour s'inscrire.
Dogwood Therapeutics (NASDAQ: DWTX) hat seine Teilnahme an der bevorstehenden D. Boral Capital Inaugural Global Conference angekündigt. Die Veranstaltung findet am 14. Mai 2025 im The Plaza Hotel in New York City statt. CEO und Vorsitzender Greg Duncan steht von 9:00 bis 15:00 Uhr (ET) für Einzelgespräche mit Interessenten zur Verfügung. Interessenten, die Treffen vereinbaren möchten, können John Perez unter jperez@dboralcapital.com für die Anmeldung kontaktieren.
- None.
- None.
Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Greg Duncan, CEO and Chairman, will be hosting one-on-one meetings on May 14th from 9:00 A.M. to 3:00 P.M. (ET).
To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics (NASDAQ: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). Interim data from the ongoing Halneuron® Phase 2 CINP study are expected in Q4 of 2025.Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.
About D. Boral Capital
D. Boral Capital LLC is an investment bank headquartered in New York which provides advisory and financing solutions to middle market and emerging growth companies. The Company has a proven track record of offering strategic guidance to clients across the globe in any sector, with access to capital from the USA, Asia, Europe, Middle East, and Latin America.
D. Boral Capital is a leader on Wall Street, having aggregated over
For further information:
Dogwood Therapeutics, Inc.
Greg Duncan
6787995724
greg@dwtx.com
http://dwtx.com
Source Dogwood Therapeutics, Inc.
FAQ
When and where is Dogwood Therapeutics (DWTX) participating in the D. Boral Capital Conference?
Who will represent Dogwood Therapeutics (DWTX) at the D. Boral Capital Conference?
What is the schedule for one-on-one meetings with DWTX management at the conference?
How can investors schedule meetings with Dogwood Therapeutics (DWTX) management at the conference?
